The combination of CXCL10 modulation with immune checkpoint inhibitors (e.g. PD-1/PD-L1 inhibitors) (415), cancer vaccines or CAR T-cell therapies may improve overall therapeutic efficacy through synergistic enhancement of the immune response (416). Here, CD274 is linked to cancer.